U.S. Department of Energy

Pacific Northwest National Laboratory

To Speed Precision Medicine, a ‘Co-Laboratory’

Scientists at PNNL use state-of-the-art nuclear magnetic resonance capabilities to conduct proteomic research such as identifying breast cancer suppressor proteins. The Lab is teaming with OHSU to form the Precision Medicine Innovation Co-Laboratory.

The Biological Sciences Division is at the heart of a new collaboration announced Feb. 14 between PNNL and Oregon Health Sciences University (OHSU).

The new OHSU-PNNL Precision Medicine Innovation Co-Laboratory, called PMedIC, will provide a comprehensive ecosystem for scientists to utilize integrated 'omics, data science and imaging technologies in their research in order to advance precision medicine-that is, an approach to disease treatment that takes into account individual variability in genes, environment and lifestyle.

PNNL has deep expertise in data science and the mass spectrometry analyses of proteins and genes. OHSU is renowned for its expertise in complex biomedical data and the design of medical trials.

"PNNL has a reputation for excellence in the technical skill sets required for precision medicine, specifically advanced 'omic' platforms that measure the body's key molecules - genes, proteins and metabolites - and the advanced data analysis methods to interpret these measurements," said BSD's Karin Rodland, director of biomedical partnerships at PNNL

 "Pairing these capabilities with the outstanding biomedical research environment and innovative clinical trials at OHSU," she added, "will advance the field of precision medicine and lead to improved patient outcomes."

OHSU and PNNL first collaborated in 2015, when they formed the OHSU-PNNL Northwest Co-Laboratory for Integrated 'Omics and were designated an NIH-funded national Metabolomics Center for the Undiagnosed Disease Network.

For a full PNNL release on the new co-laboratory, go here.

February 2018
| Pacific Northwest National Laboratory